Related Experiment Videos

EEG recordings following intrathecal iohexol administration

V E Drory1, E Avrahami, M Y Neufeld

  • 1Department of Neurology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Insights

Iohexal (Omnipaque) demonstrated safety in patients undergoing spinal imaging. Electroencephalogram (EEG) monitoring revealed no adverse neurological effects after intrathecal administration, suggesting it is a safer contrast agent.

Area of Science:

  • Neuroradiology
  • Neurophysiology
  • Pharmacology

Background:

  • Intrathecal contrast agents are used in neuroimaging.
  • Previous contrast media, like metrizamide, have shown encephalopathic effects.
  • Evaluating the safety of newer contrast agents is crucial.

Purpose of the Study:

  • To assess the encephalopathic potential of iohexal (Omnipaque) after intrathecal administration.
  • To compare the safety profile of iohexal with other commonly used contrast agents.

Main Methods:

  • Electroencephalogram (EEG) recordings were obtained from 30 patients.
  • Recordings were taken before, several hours after, and 24 hours after intrathecal iohexal administration.
  • Procedures included cervical myelography and cisternography.

Main Results:

  • No EEG abnormalities were detected in any patient post-administration.
  • Iohexal did not induce significant neurological changes detectable by EEG.
  • The contrast medium was well-tolerated.

Conclusions:

  • Iohexal is a safe intrathecal contrast medium.
  • Iohexal exhibits fewer encephalopathic effects compared to metrizamide.
  • This suggests iohexal is a favorable alternative for spinal imaging procedures.

Related Concept Videos